Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolism in adult patients at risk of clot formation.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Ledraxen, a low molecular weight heparin, is used in the management of venous thromboembolic disorders.

- Deep vein thrombosis (prevention): Reduces the risk of clot formation in patients undergoing surgery or immobilisation. - Deep vein thrombosis (treatment): Promotes resolution of existing thrombi and prevents propagation. - Pulmonary embolism (prevention): Lowers the incidence of embolic events in high‑risk individuals. - Pulmonary embolism (treatment): Assists in clot dissolution and prevents recurrence. - Hemodialysis anticoagulation: Provides safe anticoagulation during extracorporeal dialysis procedures.

Enoxaparin Sodium may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Injection‑site bruising or pain: Localised discoloration or discomfort at the subcutaneous injection site. - Minor bleeding: Epistaxis, gum bleeding or easy bruising. - Nausea or vomiting: Gastro‑intestinal upset occurring in a minority of patients. - Elevated liver enzymes: Transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major bleeding: Life‑threatening haemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT): Immune‑mediated platelet decline with paradoxical thrombosis. - Allergic reactions: Rash, urticaria or anaphylaxis. - Spinal/epidural hematoma: Bleeding in the spinal canal following neuraxial procedures.

When prescribing Ledraxen, clinicians should observe several safety considerations to minimise risk.

- Renal function assessment: Adjust dosing in patients with severe renal impairment. - Platelet monitoring: Check platelet counts regularly to detect HIT early. - Concomitant anticoagulants: Avoid or closely monitor use with other anticoagulant or antiplatelet agents. - Active bleeding: Do not initiate therapy in patients with uncontrolled haemorrhage. - Dose adjustment in extremes of body weight: Consider weight‑based dosing for obesity or low body weight. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid): - Warfarin or other oral anticoagulants: Combined use markedly increases bleeding risk. - Direct thrombin inhibitors (e.g., dabigatran): Additive anticoagulation may lead to severe haemorrhage. - Neuraxial anesthesia or spinal puncture: Heightened risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - NSAIDs or aspirin: May potentiate mucosal bleeding. - Antiplatelet agents (clopidogrel, ticagrelor): Increase overall bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs): Can impair platelet aggregation and raise bleeding risk.